Totally agree. NUH something similar.
That's why I love the fact that Craig decided to press ahead with launching Pulse at CES2023 ... and it was a pretty spectacular launch.
One can only hope that commercial negotiations are well advanced with interested parties, and with clearance now achieved these can be inked.
The partnerships announced this year, such as Invaryant and Power, would suggest we have found traction with de-centralised trials, and the Biden push for diversified trials, particularly in maternal health.
An announcement from a major player of a material purchase order, such as Bayer/Walgreens/IQVIA , will IMHO, generate the re-rate in MC.
Fingers crossed that this is announced before the US Listing announcement that will cap the SP until executed.
Add to My Watchlist
What is My Watchlist?
